Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying user area

Try for free

Cytokinetics Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Cytokinetics Inc., consolidated income statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Research and development revenues
License revenues
Milestone revenues
Realization of revenue participation right purchase agreement
Revenues
Research and development
General and administrative
Operating expenses
Operating loss
Interest expense
Loss on settlement of debt
Non-cash interest expense on liabilities related to revenue participation right purchase agreements
Interest and other income, net
Loss, before income tax provision
Income tax provision
Net loss

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Cytokinetics Inc. revenues increased from 2020 to 2021 and from 2021 to 2022.
Operating loss The net result for the period of deducting operating expenses from operating revenues. Cytokinetics Inc. operating loss decreased from 2020 to 2021 and from 2021 to 2022.
Loss, before income tax provision Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Cytokinetics Inc. loss, before income tax provision decreased from 2020 to 2021 and from 2021 to 2022.
Net loss The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Cytokinetics Inc. net loss decreased from 2020 to 2021 and from 2021 to 2022.